Endra Life Sciences Inc. · NASDAQ:NDRA
Endra Life Sciences — Investor Presentation (December 2020)
19 slides from Endra Life Sciences's investor presentation, Dec 14, 2020
Slide 1: Practical Assessment of Hepatic Steatosis for NAFLD-NASH
Practical Assessment of Hepatic Steatosis for NAFLD - NASH INVESTOR PRESENTATION DECEMBER 2020 ENDRA LIFE SCIENCES ‘See more. Do more. Live better. NASDAQ: NORA
Slide 2: Forward-Looking Statements
Forward-Looking Statements Certain statements made in this presentation are forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding the timing cof our clinical trials. our strategy. future operations, future
Slide 3: ENDRA Life Sciences' Goal
ENDRA Life Sciences’ Goal SEE MORE. DO MORE. LIVE BETTER. Commercialize Therma Acoustic Enhanced UltraSound (TAEUS®), a technology that enhances existing ultrasound systems to visualize tissue similar ta an MRI, but at SOX! lower cost and at the point of patient care. @ENDRA WASOAG: NORA 3
Slide 4: ENDRA Life Sciences
ENDRA Life Sciences PLATFORM TECHNOLOGY Opportunities in a variety of clinical applications Multiple potential revenue streams: hardware, software, services, disposables, licensing 78 IP assets! (@eNDRA {s* APPLICATION: LIVER DISEASE \4B people? affected by excess _liver fat and inflammation ~50 pha
Slide 5: Large Unmet Clinical Need: NAFLD-NASH Diagnostics
Large Unmet Clinical Need: NAFLD-NASH Diagnostics RAMPANT DISEASE, APPROACHING THERAPIES ... BUT NO PRACTICAL DIAGNOSTIC TOOLS Liver Disease: NAFLD-NASH Diagnostic Gap {st Therapies Near 1.4 billion people affected Linked to No practical diagnostic tools: Advent of first targeted therapies for obesi
Slide 6: Assessing & Monitoring Liver Fat of Billion NAFLD-NASH Patients
Assessing & Monitoring Liver Fat of 1 Billion* NAFLD-NASH Patients NO TOOL HAS BALANCED DIAGNOSTIC VALUE + ACCESSIBILITY HIGH =) OPTIMAL BALANCE = liver DIAGNOSTIC VALUE + ACCESSIBILITY > Biopsy Y - QB ° Zo ecceceeeceseseecennenneeeeeeesseesssssssssssssss 20 -- = aRGSn nnn nes anSnSnnSNONSSEOEESE =.
Slide 7: ENDRA's TAEUS: Enhancing Traditional Ultrasound
ENDRA’s TAEUS°: Enhancing Traditional Ultrasound RADIO FREQUENCY PULSES CREATE SONIC WAVES THAT QUANTITATE LIVER FAT FRACTION ¥ —TAEUS directly measures a material property of liver tissue that is only affected by the amount of fat (triglyceride), and has not been found to be confounded by fibrosis
Slide 8: TAEUS Liver: Targeting High-Value Clinical & Pharma Segments
TAEUS Liver: Targeting High-Value Clinical & Pharma Segments CLINICIANS & DRUG DEVELOPERS STRUGGLE WITH SAME MRI-BIOPSY LIMITATIONS BASTRO- RADIOLOGY HEPATOLD PHARMA & in Te eae CRO's 00,000 practitioners! 45,000 practitioners! _ 300,000 practitioners! | §0+ companies Perform 80% of TON? yearly Diag
Slide 9: TAEUS Liver Commercialization: Core Elements
TAEUS Liver Commercialization: 3 Core Elements TARGET CLINICIANS @ Sah QGA Le EMEMntros ENDRA CRM w/4000 clinician names DRIVE AWARENESS, INTEREST & Le RSNA GTBUALcal confor \ SCEASL & AASLD BUILD CLINICAL m1 ENDRA clinical eval MAPARNN Gach target market pnbed s reference sites supporting cammercia
Slide 10: TAEUS' Platform Evolution
TAEUS’ Platform Evolution: MULTIPLE POTENTIAL CLINICAL APPLICATIONS & REVENUE STREAMS TO SCALE BUSINESS HARDWARE SOFTWARE SERVICES DISPOSABLES —_LICENSING TAEUS eccessory increases utility TAEUSSW apps added to TAEUS Maintenance Fa Aepssor tt." ulin TAEUS as feature a af existing ultrasound systems
Slide 11: Future TAEUS Application: Guidance of Energy-Based Surgery
Future TAEUS Application: Guidance of Energy-Based Surgery MAP THE HEAT OR COLD SIGNATURE OF THERMO-ABLATIVE PROCEDURES FOR CANCER, CARDIOLOGY, PAIN THERMO-ABLATIVE PROCEDURES © 5° million procedures annually! grawing at 15%! CAGR, driven by aging-related diseases: cancer, pain, cardiology é ENORA ©
Slide 12: Anticipated Milestones: ENDRA Liver Application
Anticipated Milestones: ENDRA Liver Application SECURE REGULATORY APPROVALS, RAMP COMMERCIALIZATION, BUILD CLINICAL EVIDENCE 2020 2021 Y Obtain CE Mark certification * Y Surpass 70 IP assets! in portfolio ° Y Submit S10(k) application . Y Announce additional EU 6 US evaluation sites * — In-process:
Slide 13: Financial Information
Financial Information co) KEY STATISTICS (as of December tt, 2020 unless otherwise noted) Cash Balance (es of September 30, 2020) Comman Stack Price (NASDAQ: NDRA) Common Shares Outstanding Fully Diluted Shares Outstanding” Market Capitalization Management / Director Ownership** + Includes ~5M warra
Slide 14: In Summary
In Summary Targeting $21 billion unmet diagnostic need in the NAFLD/NASH market ENDRA’s solution is non-invasive, 1/50" the cost of MRI and at point-of-care Regulatory approval secured in Europe, submitted in U.S. Revenue model includes hardware, software, services, disposables and licensing agreeme
Slide 15: Appendix
‘)ENDRA APPENDIX NASDAQ: NORA 15
Slide 16: Leadership & Advisors
Leadership & Advisors MANAGEMENT Francois Michelon Michael Thornton Renaud Maloberti Amy Sitzler David Wells Chairman & CEO cro cco VP Engineering cro 20+ years in med-tech (5+ years med-tech 20+ years in med-tech. 12 years in 20 years inengineering § 30 yearsin finance and operations GE Healthcare,
Slide 17: Expected TAEUS Economic & Clinical Value To Stakeholders
Expected TAEUS Economic & Clinical Value To Stakeholders PATIENT HEALTHCARE PAYERS s PROVIDERS Ultrasound Procedure TAEUS Procedure Education & Reimbursement Clinician ony ‘self- pay) Patient presents with one or more of the TAEUS liver : for | |. Clinician submissions of TAEUS 78999 clair following
Slide 18: Liver Fat Measurement Tools: Relative Performance & Accessibility
Liver Fat Measurement Tools: Relative Performance & Accessibility Accessibilty Liver Fat (Steato: ver Bopsy Historica ald tndard for ASH Daas ++ = S psnipacteel thee dete? Blood Test (£9, ALN) + Lonel AUR spect tr ets Ua 7 ee ee RO us as on * * + Sesceptle ta nr MSH related azaes + ecw Sil Studd for
Slide 19: Sources & Assumptions
Sources & Assumptions PAGE 3 | SSOCENORA dence estimated price compored to $2.5 MA price PAGE 4 1 Ase ld isd diced patents ad pend pater apains 1 apatolagy, The economic sod cecal burden of saab tty Ir ccese inthe United Stats ard frope. Yous, Bast, Heey, Stepnova cia Hot, eckernan, 705 1 The ANGEL,
ENDRA Life Sciences — Investor Presentation (December 2020) on 6ix